Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03836053 · ClinicalTrials.gov registry record · Phase 1
Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03836053 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 23 participants.
The verdict
NCT03836053, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous infusion in patients with relapsed and/or refractory multiple myeloma, to test the 600 mcg/d dose, given as a 28-day continuous iV infusion.
Interventions
- DRUG AMG 420
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-03-04 |
| Est. Completion | 2022-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03836053
The ClinicalTrials.gov registry entry for NCT03836053 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 420 is the first listed.
NCT03836053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03836053 about?
NCT03836053 is a clinical study titled "Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma". To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous infusion in patients with relapsed and/or refractory multiple myeloma, to test the 600 mcg/d dose, given as a 28-day continuous iV infusion.
What is the current status of trial NCT03836053?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2019-03-04. Estimated completion is 2022-04-21.
What interventions are being tested in trial NCT03836053?
The interventions under investigation include: AMG 420 (DRUG).
Who is sponsoring clinical trial NCT03836053?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.